Improving Clinical Trials Through Patient Input: Outcomes of a Partnership Between Pfizer and the Parkinson’s Disease Foundation
Objective: To identify the outcomes of the partnership between Pfizer and the Parkinson’s Disease Foundation (PDF), which was designed to 1. increase understanding of the…Dopamine Agonists and Postural Disorders in Parkinson’s disease
Objective: To evaluate the relationship between treatment with DA and the development of postural disorders (CC, PS and AC) in patients with PD. Background: Stood…Tacrolimus induced parkinsonism presenting as freezing of gait and speech
Objective: Tacrolimus a calcineurin inhibitor is the most widely used immunosuppressant in post transplant patients. Mild adverse effects like tremors and parasthesia and occasionally major…Motor effects induced by D1- or D2-like receptor agonists in experimental parkinsonism.
Objective: We set out to compare movement patterns induced by systemic administration of l-dopa versus D1- or D2-class DA receptor agonists in mice with unilateral…Pharmacological modulation of mGluR5 improves dyskinesias mediated by D1 but not D2 receptor stimulation.
Objective: To determine whether pharmacological inhibition of metabotropic glutamate receptor type 5 (mGluR5) can improve dyskinesias mediated by D1- or D2-type dopamine (DA) receptors (D1R…Adding cues to a rat gambling task potentiates the increase in premature responding in response to chronic D2/3 agonist ropinirole without mitigating preference for risk
Objective: Investigating the effect of chronic administration of the dopamine D2/3 agonist ropinirole on a cued model of gambling behaviour in rats. Background: Dopamine D2/3 agonists…Neuroticism and depression is associated with impulse control disorder in Parkinson’s disease: a controlled study
Objective: Cross-sectional assessment of personality trait, impulsivity, depression and anxiety collected prospectively in Parkinson’s disease (PD) with impulse control disorders (PD-ICD) compared to a matched…Exome sequencing in patients with impulse control disorders in Parkinson’s disease: a pilot study
Objective: To identify genetic variants associated with impulse control disorders (ICD) in Parkinson’s disease (PD) Background: ICD is frequently associated with dopamine agonist (DA) therapy…Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease
Objective: We examined the impact of rs6265 and other brain-derived neurotrophic factor (Bdnf) variants in two subject cohorts: 1) early-stage Parkinson’s disease (PD) subjects from…Dopamine agonist therapy mediates relationship between psychomotor inhibition and behavioral impulsivity in Parkinson’s disease.
Objective: Evaluate relationship between psychomotor inhibition and behavioral impulsivity in Parkinson’s disease (PD). Background: Impulse control disorders can be challenging iatrogenic effects of dopamine agonist…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 16
- Next Page »